GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Debt-to-EBITDA

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Debt-to-EBITDA : -2.53 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Scinai Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.38 Mil. Scinai Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $19.43 Mil. Scinai Immunotherapeutics's annualized EBITDA for the quarter that ended in Sep. 2023 was $-7.83 Mil. Scinai Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -2.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Scinai Immunotherapeutics's Debt-to-EBITDA or its related term are showing as below:

SCNI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -74.86   Med: -2.05   Max: -1.28
Current: -1.93

During the past 12 years, the highest Debt-to-EBITDA Ratio of Scinai Immunotherapeutics was -1.28. The lowest was -74.86. And the median was -2.05.

SCNI's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs SCNI: -1.93

Scinai Immunotherapeutics Debt-to-EBITDA Historical Data

The historical data trend for Scinai Immunotherapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Debt-to-EBITDA Chart

Scinai Immunotherapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.28 -1.42 -74.86 -2.79 -2.05

Scinai Immunotherapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 -1.90 -1.91 -2.51 -2.53

Competitive Comparison of Scinai Immunotherapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Scinai Immunotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Debt-to-EBITDA falls into.



Scinai Immunotherapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Scinai Immunotherapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.382 + 21.16) / -10.499
=-2.05

Scinai Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.382 + 19.425) / -7.828
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Scinai Immunotherapeutics  (NAS:SCNI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Scinai Immunotherapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6